

About VyGen-Bio™, Inc.:

Visit us on the web at: www.VyGen-Bio.com

VyGen-Bio is a discovery-stage, cell-based immunotherapy company focused on the development of transformational technology platforms: GEAR-NK, modified natural killer cell-based therapeutics (NK cells), optimized to be co-administered with targeted antibodies; and, GEAR-Diagnostic, a companion diagnostic being developed to select patient populations most likely to benefit from targeted antibody therapies.

Headquartered in Tampa, Florida on the campus of the H. Lee Moffitt Cancer Center, VyGen-Bio is a majority-owned subsidiary of Vycellix, Inc (www.Vycellix.com). The Company's platforms were discovered by scientists at Karolinska Institute (KI), Stockholm, Sweden that collaborate with VyGen-Bio. Additionally, VyGen-Bio is a member-partner in "NextGenNK", an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI and funded by Sweden's innovations agency, Vinnova. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine.

Platforms:

- GEAR-NK:** Gene-Edited Antibody Resistant NK cells (GEAR-NK) are being developed as novel cancer treatment to allow for modified NK cells to be co-administered with targeted monoclonal antibodies ("mAbs"), which in the absence of the GEAR-NK would otherwise be neutralized/eradicated by mAb therapy due to common receptor shared by both malignant cells and NK cells. GEAR-NK is expected to represent a combination cancer therapy with the potential for significantly improved outcomes for patients. The GEAR platform also holds the potential to modify hematopoietic stems cells (HSCs) in combination with mAbs to improve bone marrow transplant outcomes in the treatment of a broad range of hematological malignancies.
- GEAR DIAGNOSTICS:** Expanding on the GEAR-NK platform, a companion diagnostic is being developed as an *in vitro* screening tool to pre-determine which cancer patients are most likely to benefit from targeted mAb therapies, either as monotherapy or in combination with GEAR-NK. The GEAR-Diagnostic platform is being designed to ensure optimal patient selection, which would result in significant savings to healthcare systems and prevent patients from being subjected to ineffective therapy along with the associated side-effects which are sometimes adverse.

VyGen-Bio Leadership:



Evren Alici, M.D., Ph.D., Chairman and CEO
Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm



Hans-Gustaf Ljunggren, M.D., Ph.D., Chief Medical Officer
Former Dean of Research, Karolinska Institutet and founder of the Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm



Arnika K. Wagner, Ph.D., Chief Scientific Officer
Assistant Professor, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm



Douglas W. Calder, President
Board Member, NextGenNK; Board Member, BioFlorida; Member, Society for Natural Immunity

VyGen-Bio, Inc.
at Moffitt Cancer Center, Fowler Campus
4105 E. Fowler Ave, Tampa, FL 33617, USA

Douglas W. Calder, President
Phone: 772-418-6302
Email: dcalder@vycellix.com